Skip to main content

From the Helm: CSL’s David Lamont on the biotech giant’s bright future

Jessica Amir
February 20, 2020

In the latest instalment of Bell Direct’s From the Helm series, Jess has a chat with CSL’s CFO David Lamont.

David gives the inside scoop on CSL, the market leader in the blood plasma and vaccine market. Additionally, he explains CSL’s own products, programmes and partnerships, and the steps taken by the medical giant to tackle coronavirus.

Plus, he sheds some light on the unique situation the broader pharmaceuticals industry finds itself in when it comes to new competition, as well as CSL’s future proofing strategy.

Morning Bell 12 August

Grady Wulff
August 12, 2024

Weekly Wrap 9 August

Grady Wulff
August 9, 2024

Morning Bell 9 August

Sam Kanaan
August 9, 2024

Morning Bell 8 August

Bell Direct
August 8, 2024

Morning Bell 31 July

Sam Kanaan
July 31, 2024

Morning Bell 30 July

Sam Kanaan
July 30, 2024

Morning Bell 29 July

Grady Wulff
July 29, 2024

Weekly Wrap 26 July

Grady Wulff
July 26, 2024

Morning Bell 26 July

Sam Kanaan
July 26, 2024

Morning Bell 25 July

Grady Wulff
July 25, 2024

Morning Bell 24 July

Grady Wulff
July 24, 2024